Top

BMC Cancer

Published in:

Open Access 01-12-2004 | Research article

Wnt1 is epistatic to Id2 in inducing mammary hyperplasia, ductal side-branching, and tumors in the mouse

Authors: Susan Marino, Claire Romelfanger, Yoshifumi Yokota, Roel Nusse

Published in: BMC Cancer | Issue 1/2004

Abstract

Background

During pregnancy, the mammary glands from Id2 mutant animals are deficient in lobulo-alveolar development. This failure of development is believed to be due to a proliferation defect.

Methods

We have asked whether functional Id2 expression is necessary for Wnt induced mammary hyperplasia, side branching, and cancer, by generating mice expressing a Wnt1 transgene in an Id2 mutant background.

Results

We show in this work that forced expression of Wnt1 in the mammary gland is capable of overcoming the block to proliferation caused by the absence of Id2. We also show that Wnt1 expression is able to cause mammary tumors in an Id2 mutant background.

Conclusions

We conclude that functional Id2 expression is not required for Wnt1 to induce mammary hyperplasia and mammary tumors.

Available only for authorised users

Grandori C, Cowley SM, James LP, Eisenman RN: The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000, 16: 653-699. 10.1146/annurev.cellbio.16.1.653.CrossRefPubMed

Norton JD, Deed RW, Craggs G, Sablitzky F: Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 1998, 8: 58-65. 10.1016/S0962-8924(97)01183-5.PubMed

Yokota Y, Mori S, Nishikawa SI, Mansouri A, Gruss P, Kusunoki T, Katakai T, Shimizu A: The helix-loop-helix inhibitor Id2 and cell differentiation control. Curr Top Microbiol Immunol. 2000, 251: 35-41.PubMed

Mori S, Nishikawa SI, Yokota Y: Lactation defect in mice lacking the helix-loop-helix inhibitor Id2. EMBO J. 2000, 19: 5772-5781. 10.1093/emboj/19.21.5772.CrossRefPubMedPubMedCentral

Willert J, Epping M, Pollack JR, Brown PO, Nusse R: A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol. 2002, 2: 8-10.1186/1471-213X-2-8.CrossRefPubMedPubMedCentral

Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, Phillips WA: Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem. 2001, 276: 45113-45119. 10.1074/jbc.M107742200.CrossRefPubMed

Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988, 55: 619-625. 10.1016/0092-8674(88)90220-6.CrossRefPubMed

Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P: Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature. 1999, 397: 702-706. 10.1038/17812.CrossRefPubMed

Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999, 398: 422-426. 10.1038/18884.CrossRefPubMed

10.

Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994, 369: 669-671. 10.1038/369669a0.CrossRefPubMed

11.

Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500.CrossRefPubMed

12.

Mori S, Inoshima K, Shima Y, Schmidt EV, Yokota Y: Forced expression of cyclin D1 does not compensate for Id2 deficiency in the mammary gland. FEBS Lett. 2003, 551: 123-127. 10.1016/S0014-5793(03)00906-2.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/4/91/prepub

Title: Wnt1 is epistatic to Id2 in inducing mammary hyperplasia, ductal side-branching, and tumors in the mouse
Authors: Susan Marino
Claire Romelfanger
Yoshifumi Yokota
Roel Nusse
Publication date: 01-12-2004
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-4-91

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2004

Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells

G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer

CD155/PVR plays a key role in cell motility during tumor cell invasion and migration

Characterization of a novel large deletion and single point mutations in the BRCA1gene in a Greek cohort of families with suspected hereditary breast cancer

Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines

An unusual pathological finding of chronic lymphocitic leukemia and adenocarcinoma of the prostate after transurethral resection for complete urinary retention: case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer